In the active role of hedge fund Third Point LLC has three board seats and a share of 9.5% in the pharmaceutical ligands, Inc specialty pharmaceutical company. The third point is believed that the ligand was a strong drug portfolio and pipeline, but he was a very underrated because of poor management. After obtaining board representation, the third point is convinced that the other directors to try to sell the company. Six months have passed since the ligand began soliciting applicants, but no buyer was. Upon the sale of the company appear to have stalled, and the third point is to decide whether to restart the bidding process, to keep the long-term position, or leave. "Hide
by Nabil N. El-Hage, Michael Gorzynski Source: Harvard Business School 22 pages. Publication Date: November 27, 2007. Prod. #: 208019-PDF-ENG
Related Case Solutions & Analyses:
Trome: News for the Base of the Pyramid
People Management The Mantra for Success: The Case of Singhania and Partners
Managing Inventories–Reorder Point Systems
New Schools Venture Fund (A)
Latin American Factory Start-Up
Chez Panisse: Building an Open Innovation Ecosystem
Pfizer and AstraZeneca: Marketing an Acquisition (A)
KwikAxess: A New Business Model
The Era of Global Solution Networks
A City’s Desert: No Apples in the Big Apple? (B)
